What Researchers Did
Researchers conducted a structured review of 284 abstracts published between June 1999 and May 2009 to update evidence-based recommendations for migraine prevention treatments.
What They Found
The review identified 49 Class I or II articles, with 15 focusing on nontraditional therapies, NSAIDs, and other complementary treatments. Petasites (butterbur) was found to be effective (Level A) for migraine prevention, while fenoprofen, ibuprofen, naproxen, feverfew, magnesium, and riboflavin were probably effective (Level B). Montelukast was established as probably ineffective (Level B).
What This Means for Canadian Patients
Canadian patients experiencing episodic migraines may consider discussing Petasites (butterbur) with their healthcare providers as an effective preventive treatment. Additionally, other options like ibuprofen, naproxen, magnesium, or riboflavin could be explored as probably effective complementary therapies to reduce migraine frequency and severity.
Canadian Relevance
This guideline was developed by American medical societies and does not have a direct Canadian connection. However, the evidence-based recommendations for migraine prevention are broadly applicable to patients worldwide, including those in Canada.
Study Limitations
A limitation is that this guideline's recommendations are based on studies published up to May 2009, meaning more recent evidence may not have been included.